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Growth or altered mrfaboflm of nonmyoryte e&r (cardi~e tX,m- 
blasts, “aseldar Smwth musete and O”dcAllelial eel&, alters mya 
cardial and vaxular ~trwtwre (remcdrtll) and function. How 
ever, the precise role8 of circulating and lorally generated factors 
roeh as angloteorio U, atdwterone and cndotbelin that regulate 
growth and metaboltrm of nmmtymyte 4s have yet to bo fully 
elucidated. Trials of pbarlnaeelegic therapy aimed at preventing 
structural remodeling and repairing altered myecardiel ~trueture 
During the early 19th century, medical research focused on 
understanding the structure! basla of disease (3: z;;osed to 
its functional basis, in which persistent structural abnomtal- 
ities were not thought to be involved). In the late 19th and 
early 20th centuries, Vircbow (I) and others identified cells 
as the structural basis of tissues and disease, laying the 
ground work for the study of anatomic pathology in which 
the importance of structurally remodeled tissue. mediated by 
allered cell behavior. was recognized. 
The homogeneity of cellular and structural elements of 
the heart sod circulation is altered by disease. This remod- 
eling of tissue structure, mediated by transcriptional. trans- 
lational or pasttranslational events within resident cells and 
extrarellular space, may be adaptive or pathologic. Cardiac 
axjocyte growth accompanying increased myocyte work 
load, for example, is an adaptive alteration in myocardial 
structure seen with athletic training. In contrast. left ventric- 
ular hypettrophy in hypertension represents the major risk 
factor associated with the subsequent appearance of symp 
tomatic heart failure (2). As exemplified by left ventricular 
hypertrophy due to exercise training, myocyte growth need 
not prove pathologic. Instead. the growth or altered metab- 
olism of nomnyocyte cells, such as cardiac fibroblasts, 
vascular smooth muscle cells and endothelial ceils, will alter 
myocardtal structure and ultimately its function. Factors 
that regulate the growth and metabolism of nonmyocyte cells 
require elucidalion. Because nonmy~cyte cell involvement 
can be found in either the hypertmphied or the nonhyper- 
trophied ventricle, it appears that such cells can be at&ted 
independeni ofmyocyte gmwtb. 
Tbcse pnnc~pks are fundamental to the concept of inter- 
ventions directed to protect against or induce repair of 
disease in the herot and circulation. The tertosprofr~live and 
repvralivr are applied to measures u ed to protect and repair 
the heart and vasculature, as well as the kidney. In protect- 
ing the heart from injury, for examp!e. it is sssumed that the 
integrity of its cells can and will be preserved. In repairing 
the heart, however, an intervention is used to restore dir- 
eased tissue to or toward its nomtoi :!mctural organization 
and function. 
These concepts can be applied to left ventricular hyper- 
trophy, the primary maoifestatio~~ of preclinicai disease 
associated with adverse cardiovascular outcomes. For ex- 
ample, prevention his in patients with systemic hyperten- 
sion are designed to reduce the risk of myocardial iofarcticn 
and heart failure. Phartoacologic agents may also be wed to 
repair established left ventricular hypertropby and altered 
cardiovascular snucture PS addressed in lreormenr rrials. 
The purpose of this review is to consider broadly our 
conem understanding of the structural remodeling of the 
cardiovascular system and kidney in hypertension. myocar- 
dial failure and diabetes. We also examine the efficacy of 
vartous pharmacologic interventions that may protect the 
heart and vasculature against injury or provide reparation of 
their altered structure m these setlines. 
To address these issues the authors of this review met on 
June 8 and 9, 1991, in Chicago, Illinois. Each had prepared 
ins seaion cf thir report befGm the meeting so it could be 
vigorou:!;, ::tated and consensus could be reached during 
thr meeting on the data presented here. Because of space 
constraints, we have limited literature citations but have 
provided recent publications and relevant reviews on previ- 
ous work. 
Cells, Their Growth and Altered Behavior 
The myocardium is composed of cardiac myocytes and 
nonmyocyte cells, which include endothelial cells, vascular 
smooth muscle cells and fibroblarts [Fig. I). The growth or 
altered metabolism of these cells can lead to &ctural 
remodeling of the myocardium. These nonmyocyte cells are 
also found in the vaswlature. Here, too, they determine the 
structural organiza!ion of these tissues. 
Myocyre Growth and Ventricular 
Wall Remodeling 
Mywyte growth. Muscle cctls constitute approximately 
85% of ventricular tissue, and alterations in myocyte size, 
shape and number are the major determinants of changes in 
ventricullrPImt~,dons resulting from an increase in pressure 
or volume load, or both, on the myocardium or hormonal 
stimulation (31. More important. the hypenrophic response 
is determined not only by the extent and nature of the 
stimutus (31, but also by its duration (4 and the age of the 
animal. Increased ventricular pressure in the adult heart 
induces concentric hypertrophy in which wall thickness 
increases without chamber enlargement. This phenraenon 
is accomplished by a lateral expansion of myocytes ,cdh no 
change in cell number or average royocyle length. At the 
subcellular level, this growth process is characterized by a 
proliferation of myofihrillar units through the parallel addi- 
tion of newly formed structures of approximately equal size. 
In contrast, an increasing vobune load on the heart induces 
enlargement of the ventricular chamber without a relative 
increase in wall thickness, that is, eccen!ric hypcrtrophy. 
Chamber enlargement seems to be caused by lengthening of 
the myocytes through replication of sareomeres in series 
with only slight variations in myocyte cross-sectional area 
and with no change in rarcamere length. Finally, when the 
ventricle is exposed to an increase in both pressure and 
volume, myocytes increase in both diameter and length: and 
one of these dimensional variables may expand more than 
the other, reflecting the prevailing nature of the mechanical 
stimulus. Hypenrophy can also occur in association with a 
variety of growth-regulating factors, such as norepinephrine 
and angiotensin II, although the mechanisms of myocyte and 
wall remodeling have not yet been fully characterized (5). 
The mechanisms of ventricular wall remodeling described 
thus far referto concentric or eccentric cardiac hypertrophy, 
or both, in a state in which load is fully compensated and that 
has been achieved by specific changes in size and shape of 
preexisting cells without affecting the overall number of 
myocytes in the .a ~n~+rle. There is growing evidence sug- 
gesting that long-term pressure overload produced by pul- 
monary artery banding (6) and renal hypertension (7) may 
initiate hyperplastic growth of myocytes in the adult heart 
where new cells art: added in pamlkl. !eadiq to mural 
thickening through the lateral insertion of new cells and to a 
decreasein the~ma$nitude of load cm B cellular basis. 
Whether myocyte hype&& is an important component of 
the late stages of volume hypertrophy is still unanswered. 
Ventricalararadaotation. The characteristics of ventricular 
adaptation just dis&sed do not take into account an essen- 
tial component of wall remodeling that accompanies either a 
diffuse or a focal loss of myocytes, such as occurs with 
myocardial isehemia (8). acute myocardial infarction (9) or 
aging (IO). Myocyte necrosis imposes an additional load on 
remaining cells that in torn enlarge to compensate for the 
loss in muscle mass. These forms of reactive growth can 
only be estimated at the organ level as tissue weight or 
volume measurements alone fail to recognize myocyte hy- 
pertrophy (9). 
Thus. cardiac myocyte 8mwth is responsible for major 
anatomic changes resulting from pathologic wnditions af- 
fecting the loading state of the myocardium. The nonmyo- 
cyte compartment of the wall participates in this process 
Figure 2. Endotbeli”m-derived Yasoacd”e substances. AA = ata- 
chidonic acid: ACE = angiorensin-convening e zyme. ATG = 
angiotensinogen: ACh = acetylcholine: AT I and AT II = angioten- 
sin I and II, respectively; CAMP and cGMP = cyclic adenosine md 
cyclic guanosine mono~bospbate. r speclively: EDCF = endorbe- 
liumderived constricting fa.ctor(sl: EDHF = endothelium-dewed 
hyperp&rizing factor: II,. Hi = histaminergic receptor: K* = 
potassium; M = muscsrinir cccptor; Ns- = sodium: NO = mtric 
oxide; P, = purincr~ic receptor; PCll = prortacyclin: S, = *era- 
toner&c receptor: T = thrombm receptor; V = vasopressinergic 
relxptor. Reprinted, wtb permisnon. from Luscher TF [III. 
because growing evidence points to the possibility that 
restructuring of collyen in the myocardtum 301 only aU?c!s 
the mechanical properties of the rnusclc. but also plays no 
integral rote in global ventricular ranodeling of the over- 
lo&d heart. 
Various factors !hat oarticioste in the reculation of vas- 
cular tone and gmwth are synthesized witbyo the endothe- 
lium (I I) (Fig. 2). Svecificallv, endothelial cells release both _ 
endotheliom-derived relaxing factor. which serves as a po- 
tent vasodilator and antimitogenic factor, and the peptide 
endothelin. a potent vasoconstrict.x and mitogcnic factor. 
Congestive heart failure is characterized by low c~!tac 
output. avid sodium retention, marked activation of the 
renin-angiotensin-aldostemne system with enhanced wscu- 
Iar tone and myocardial growth. Recent reports uggest hat 
endothelium-derived relaxing activity may be functionally 
present and selectively enhanced in this setting. Despite its 
possible presence in congestive heart failure, excessive 
vasoconstriction is its hallmark; and this sectioo will focus 
on the role of enhanced endothelinlike activity in tots syn- 
drome. A recem review has addreasrd ibis subject in detail 
(12). 
Preproendothelin. iMessenger rihonucleic acid (RNA1 en- 
coding for preproendothelin has been found to endothelial 
cell5 of large vessels and capdlaries in various mamma!ian 
t~ssw, mcludmg the hean (131. In \iitro studies have dem- 
on9nted enhanced prcprocndothelin gene production in 
rerpunrc to decreased shear 5trcss. epinepbrine, thrombin, 
angmtensin II and other mechanical and rbemwd ctimu- 
lanrc. Preproendothelin is cleaved by an cndoprptidaie to 
form proendothelin, and 8he final step IS brooght about hg 38 
endothelin-converting enzyme. 
Endothelin. Endothzlin exerts its biologic actions 
through a swcitic receptor on the cell membrane with 
bindI& we; identified i the heart. lung. kidney, adrenal 
gland and brain (1% The intracellular mechaaism of action 
of endothclin is linked to increases in inositoi iriphosphate 
and diacylglycerol. with concurrent increases in intracellu!ar 
calcium and activation of protein kinase C. These aclions 
ifsuIt in marked and sustained vasoconstriction. In addition 
‘c ~~~nccw-~ti~rnr propelties. en4orhelin has functionally 
important cardiovascular. renal and endocrine actions (1%. 
Endothelin may also stimulate release of both renin and 
aldosterone and enhance conversion of aogiotensin I to 
angiotensin II in endothelial cells. 
A further important action of endotltelin is derived from 
its mitogenic potential. which could contribule lo st~caml 
changes within the cardiovaxular system. It has been re- 
porled that esdothelin stimulates proliferation f rat vascular 
smooth muscle cells, fibroblasts, glome&o mesangial and 
human carcinoma cells wilh tbc expression of proto- 
oncogener (c-myc, c-#OS) in these cells (16). Such mitogeoic 
actions may be mediated thmurh calcium influx. Such 
diverse biologic actions support the view that endothelin. in 
addttion to its vasoactive and endocrine actions. is an 
important autoaine+aracrine substance that participates in 
the regulation of cellular Proliferation. 
Role of eodolbelitt in coogestive heart failure. The role of 
endothelin in the pathophysiology of chronic congestive 
hean failure is now supported by reports of its plasma 
elevation in human and experimental heart failure (171. In 
the rcnio-angiotensin-aldosterone systen~, the vasoconstrict- 
mg effects of endothelin in a similar fashion. may be bene- 
f&l early in heart failure by augmenting preload through 
venoconstriction and sodium retention and by increasisg 
systemic vascular resistance to maintain perfusion pressure. 
With time, however, the long-term effects of endothelin 
activation, including the peptide’s action as a growth factor, 
which may contribute to cardiovascular emodeling, may 
become excessive and may account for a continuing deteti- 
oration in cardiac function. 
Preventlog 01 Mocklog the etTeets of rodotbelin. On the 
oresumotion that it miaht be beneficial to prevent or t  block 
ihe e&s of endorhelin in hear1 failure, various strategies of 
reoarr&o’. m. --=--- .- _...:._.~ ___I:__ ^” ^ _.,,I_P J wwy. n, IIIcI,LIuII~” SLIIICI, “II L”..,‘.‘. 
enis& that converts oroendothelin to endorbelin-I. It is 
possible that an inhibitor of endothelin-convert@ enzyme 
will be developed. Decreasing the stimuli to endothelin 
secretion would he another possible way to influence endo- 
thelin. Angiotensin-converting enzyme IACE) inhibitors 
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may lessen endothelin efferts by decreasing the amount of 
angiotensin 11 gensrated. Development of endothelin recep- 
tor blockers is another possibility. Other avenues might be to 
enhance substances known to counter-regulate endothelin 
action (such as nitrates and atrial natriuretic factor) by 
increasing intracellular accumulation of cyclic guanosine 
monophosphate and calcium antagonists to decrease intra- 
cellular calcium influx. 
Because a pnmary function of the endothelial cell is its 
paracrine role of regulating vascular smooth muscle cell 
function, we focus next on the activity of the vascular 
smooth muscle cell as it relates to heart failure and structural 
remodeling. 
Vascular Smooth Muscle 
Vascular smooth muscle cells have both contractile and 
synthetic functions and play a key role in the changes in 
vascular structure associated with hypertension, atheroscle- 
rosis and vessel wall injury. An understanding of the mech- 
anisms controlling vascular development is essential to an 
understanding of these pathologic conditions. 
Angiogenesis. Classically, the fundamental process in an- 
giogenesis is the mitotic division of existing endothelium and 
subsequent capillary development, a process probably de- 
termined mainly by the metabolic requirements of the vas- 
cular bed concerned (18). Fibroblasts then come into appo- 
sition with the more proximal and distal capillaries and 
differentiate into smooth muscle cells which, apart from 
allowing the vessels to adjust their caliber, also synthesize 
the proteins forming the connective tissue matrix. Thus are 
formed the arteries and veins, but the factors governing their 
subsequent development are still poorly understood. Plasma 
growth factors may play a role, for apart from the well 
established evidence for growth factors causing prolifera!ion 
or growth of smooth muscle cell cultures (19,20), there are 
now indications that also under in vivo conditions, angioten- 
sin II can cause pressure-independent vascular growth in 
rats (21). 
Physical factors, such as Incal intravascular pressure and 
flow. These factors also appear to affect vascular structure. 
Evidence for an initiating role for intravascular pressure 
comes from the close correlation seen between intravascular 
pressure and the ratio of vesse! media thickness to lumen 
diameter (22) and from the increase in this ratio in response 
to interventions that increase blood pressure (23.24). Evi- 
dence for an initiating role for intravascular flow comes from 
the finding that a reduction of flow causes a decrease in 
vessel diameter (25) that is endotheiial dependent (26). There 
is also evidence th-* ;- yI . ..cro.,d flow rcsdlts in an incrcasc in d-r” 
vessel diameter (24). The mechanisms by which these phys- 
ical factors stimulate growth is not known. 
Pathologic changes in the vasculature affecting vascular 
smooth muscle cells. These changes include changes in the 
number, size or arrangement of smooth muscle cells within 
the media and migration of smooth muscle cells into the 
intima and their subseotlent proliferation. Changes within 
the media are commrnly seen in hypertension, whereas 
intimal changes are Formally associated with hypercholes- 
terolemia and atherosclerosis and are confined to the larger 
arteries. However, there is evidence from experimental 
models of hypertension that increased blood pressure itself 
causes proliferation of smooth muscle cells in the intima 
(27). This proliferation may possibly be the result of endo- 
thelial injury caused by high intravascular pressure. Thus, in 
this respect, hypertensive and atherosclerotic vascular dam- 
age may share a common etiology (28). Furthermore, some 
of the features seen in large arteries of experimental hyper- 
tension, such as endothelial cell and smooth muscle cell 
proliferation, increased permeabdity , monocyte accumula- 
tion, deposition of connective tissue matrix and intimal 
thickening, can also be observed during the ~locess of 
wound healing and can represent appropriate responses to 
injurious stimuli (27). 
Fibroblasts 
Fibrillar collagen. Fibrillar co:!agen is a major structural 
element contributing to the physical integrity of the cardio- 
vascular system (29). In its absence or when its fibrils are 
improperly crosslinked, aneurysmal dilation and rupture of 
the heart or vasculature follow. Conversely, a disproportion- 
ate rise in collagen concentration or fibrosis adversely raises 
tissue stiffness and promotes myocyte atrophy and is there- 
fore a major contributor to the pathologic remodeling of the 
cardiovascular system. 
Fibrosis can be found in the hypertrophied ventricle, 
whose work load is increased, as well as in the nonhyper- 
trophied ventricle with a normal work load, indicating that 
regulation of fibrous tissue is distinct from myocyte growth 
(3n). That myocardial collagen concentration is increased in 
certain disease states but not in others (31) also supports this 
view. 
Fibroblasts. Fibroblasts reside within the interstitial 
space of the myocardium and the walls of arteries and veins. 
They contain the messenger RNA for types I and III 
coilagens, the major fibrillar collagens of the heart and 
circulation (32). Fibroblasts play an important role in the 
structural remodeling of the heart and circulation in various 
cardiovascular diseases. In cases of parenchymal cell injury, 
they mediate a replacementjibrosis that restores structural 
integrity to the tissue. However, their potential for growth 
and enhanced collagen synthesis, in the absence of cell loss, 
cause a disproportionate accumulation of fibrillar collagen. 
This reactive fibrosis or collagenosis distorts tissue struc- 
ture, increases tissue stiffness and electrically isolates myo- 
cytes from each other. 
Reactive myocardial fibrosis. Reactive myocardial fibro- 
sis includes perivasculor,/ibrosis of small and medium-sized 
intramyocardial coronary arteries and is usually associated 
with interstitialfibrosis. Perivascular fibrosis is also found in 
systemic xgans. In vivo studies suggest that in acquired 
hypertension this reactive fibrosis 13 related to long-term converting enz,me is preseni to masse s*cess. is uhiqut- 
elcvntions in circulaung miocralocntticoid~ iaidosterone and tously dtatnbutcd and is thereforr not rate Ihmttmg. Unttt thts 
denxycnrticos!arone): it &o accompames the ndmmwrd- rateJnniting step m the renin-aogmtensin caccade is more 
lion of anabolic steroids. Less freqoenr exprw.ion~ of fully es!abhshed. tt is more likely that trssoc rrnin is of renai 
reactive fibrosis include endom)o~wdiol fihroris and c!t~ “rwc and remamo the only defined r&e-limiting step for 
dncardioljbrosis. actitatmn of fhtr hormonal cascade that occurs in the 
Several different tibroblast forms are identifiable by mor- :nte!stitud fluid of cardiac and vascular tissues. 
phologic criteria and phenotypic marken. Mgofibroblaats. 
an integral component of granulation tissue. are transformed 
tibroblastr that possess contractile protein tilamcnts. These Localixuion of Cardiovascular An.@fensin- 
mesenchvmal cett~ are an imoortant comaoncnr of the Comwrirq Emyme 
wound-h&ding response and contraction of s&x tiswe (331. An rn vitro autoradioaraohic method has bee” develoxd 
Fibroblasts of the cardiovascular system probably pas- 
sess membrane~~bound angiotensin teceptors. In addition, 
to mea~ore angiotensin-convening enzyme (ACE) in situ in 
tissue section, wine a tadioiodinated derivattve of the ACE 
ftbroblasts of the aorta have been shown-to have type I and mhtbitor. hsmopril. This compound bmds to the active site 
type It conicoid receptors within theu cyrorol although the of ACE and permtts its localiration and quantitation in tissue 
biologic response to their activation ha; not been proved rcctions (36.37). Binding of unlabeled ACE inhibitors, given 
(34). The contribution of peptide and sword her rnone recep- in *ivo. can also be used as they generatty remain ti&tty 
tar activation in these noncla%ic target cells to the structural bound to the ACE binding site in tissoe sections ex viva (38). 
remodeling of the cardiovascular syrtem has not been sys- The degree of .4CE inhibition is calculated by comparison 
tematically addressed. Polypeptide growth factors are wtth ACE binding in control animals (35) or calculated after 
known to influence fihmblast growth and collagen mettaba- removal of the hound drug (39). Angiotensin-converting 
lism. On the basis of this information. insights otto the enzyme ws localized in the rat heart by quantitative in vitro 
modulation of fibroblast activity and collagen metabolism autoradiography (401. Using the binding association canrm”~ 
may emerge for the purpose of protecting againci. or rcpair- (K,) of the radioligand. significant ditYere”ccs were iound 
ing, abnormal cardiovascular stroctore. between K, values for atria and ventricles with a rank order: 
Collagen degradation. Fibroblasts are also responsible atria > lung > ventricles (41). 
for degrading fibrillar collagens in the cardiovascular system. Density of ongiotetuln-convertit~g enzyme (ACE). The 
Proteolytic digestion occurs withtn both fibroblasts and the highest drnstty of ACE in the heart was found on valve 
extracellular space (35). Enhanced formatton or activation of leaflets. in marked contrast to the very low density of ACE 
extrncrllular collagenase degrades ftbrillar cottage” (coIla- labeling in Ihe cndmxdium. Intramyacardial coronaq ar- 
genolysis) and can lead to myocardial rupture or diiatcd trrier :dso showed dense ACE tabeti”~& The righr “,ri”m had 
cardiopothy. Alternatively. collagen degradation can be in- a moderate density of ACE labeling, which was higher than 
vaked to reverse a disproportionate rise in collagen coocen- that of the left atrium and the ventricles. In contrast to the 
trotion as part of the ptocess termed cardioreparation. endocardium. the endothelial and adventitial lavers of the 
Kesults of such treatment trials are dtsoussed later. aotia and pulmonary artery displayed high densities of ACE. 
Because the renin-aoglotPsrin-aldostemne system may with very low dpnsily in the media. Angiotensin-cowerring 
pi;j’ an important role in the structural remodeling of the enzyme was not detected in either the sinoatrial or the 
cardiovascular system and because it appears to reprwent atrioventrrcutar node (40). These results reveal a markedly 
an additional predictor of morbid events. it has received nonuniform ACE localization in the rat heart and suggest 
special recognition in this report, independent of left yen- possible sites for local generation of angiotensin II or bra- 
tricular hypertrophy. This includes a consideration of ao- dykinin or other peptides. 
giotensin-converting enzyme found wthin the heart and The cardiac ACE level is greatly increased after expcri- 
VaSCUlatUre. mental myocardial infarction in rats. This increase is evident 
at 4 weeks and persists for a Ieat 6 months; it is greatest in 
In~uences of Cardiovaschr Tissue the fibrous scar’kssue “f the free left ventricular wall infarct. 
Angiotensin-Converfing Enzyme 
Treatment with enalapn‘l for 4 weeks after coronary ligation 
inhibits cardiac ACE levels including the high levels found in 
Aaaiotattsin.eonverti emvote (ACE). This enzyme re- the scar in the left ventricular free wall 1421. Inhibition of 
quixsattgiotensin 1 to p;ducE ang/otcnria ::. Attgi&osin 1 caidiai ACE may iootribu:c :o : eardtoprotcctivc rok for 
is produced only by the action of renm, the rate-limiting step ACE inhibiton. 
in the cascade that produces angiatensin Il. Physiologically Angtoteosin.wwerting anzynw inhibition in the heart. 
meaningful amounts of locally synthesized renin are neces- This inhibition was studied ex viva after oral administration 
sary for a tissue to have a local reninangiotensin system. of lirinopril. rofenopril and captopril to rats to study the time 
Documentation of myocardial or vascliar generation of course, degree and sites of ACE inhibition by quantitative m 
renin has not been consistent. However. angiotenrtn- vitro autoradiography (43). ACE activity in all regions of the 
heart was greatly reduced 4 h after administration of lisino- 
pril and zofeoopril and had only partially recovered toward 
&ml levels at 24 h. After captopril treatment, ACE 
activity in the heart was partially inhibited at I h and had 
fully recovered toward control levels in most regions at 24 h. 
These results suggest hat these inhibitors block ACE in all 
regions of the heart without regional seiectivity. 
Altered Tissue Structure and Intervention: 
Results of Prevention and Treatment Trials 
Given the importance of disease in altering the structural 
organization ofthe heart and cardiovascular system and thus 
its funchon, pharmacologic interventions hould be selected 
to prevent or repair this structural rcmcdc!ing with an intent 
to achieve a favorable outcome, measured in terms of organ 
~trucuue, function and morbid and mortal events. Because 
systemic hypertension, heart failure and diabetes mellitus 
are major health problems, we emphasized lhese disease 
states in this review. The results of prevention and treatment 
trials in each of these disease states are considered with a 
view toward their impact on the heart, ~a~~~lat~re and other 
organs such as the kidney. Clinical results are supplemented 
with experimental find& whenever an important gap in 
knowledge exins. 
Hypertension 
Heartlpreventiw trials. Using echocardiography, the 
Framingham study (44) showed a high prevalence of in- 
creased left ventricular mass in humans. In prospective 
follow-up studies (45.46) increased !eft ventricular mass WI 
a stronger predictor than any conventional risk factor of 
cardiovascular morbid events, cardiac death and all-cause 
mortality with the exception of age. This was true for both 
women and men and the relation was independent of the 
presence of hypertension (45-47). Funhcr substratification 
of risk was obtained by considering specific left ventricular 
geometric patterns, with the highest risk ~evcl in patients 
with concentric hypertrophy and the lowest in those with 
normal left ventricular geometry (46). High renin-sodium 
profile status was recently shown (48) to be an addGnal 
predictor of myocardial infarction in hypertensive patients, 
independent of electrocardiographic (ECG) left ventricular 
hypertrophy or other conventional risk factors. 
Several variables potendally amenable to pharmacologic 
or nutritional lifestyle modification heve been shown to 
stimulate left ventricular hypertrophy. In addition to clini- 
cally recognized hypertension (4449). these variables in- 
clude blood pres& elevation during ordinary activity 
or physical exercise (50). obesitv 144.49). dietarv salt in- 
tak; ckY.51) and elevated blood &cos~ty (52). E&tia.l or 
secondary hypertension with high renin-angiotensin- 
aldosterone activity or circulating catecholaminc levels have 
not been associated with greater degrees of left ventricular 
hypetlrophy thrn those found in unselected palients wi:h 
systemic hypertension (53). Preliminary studies in hypcncn- 
sive patients have shown parallel reduction of left venlricu- 
lar mass and blood ~msure by weinht loss (541 or restriction 
of salt intake (55): Similarly; numerous experimental and 
clinical studies l56.57) have shown that antihypertensive 
drug studies can reduce left ventricular mass, 
the devel- 
opment of subsequent hypertension (61.62). Whether these 
hkreditary tend&es todevelop hypertension and left ven- 
tricular hypertrophy can be interropted by rneasure~ such as 
prevention of weight gain or cxccssive salt intake remains to 
be determined. 
Heartirrealment rials: left ventricular hypertrophy. 11 is 
presumed, although no definite proof exists, that reversing 
left ventricular hypertrophy by antihypertensive drug ther- 
apy will be beneficial, as recent evidence suggests. Analysis 
of preliminary experience by Karen et al. (63) showed that 
re~ersat or &v&lion of left ventricular hypertrophy. as 
detected by echocardiography, during treatment of hyper- 
tension resulted in a much lowerfrequency ofcardiovascular 
events (5%) than that of patients in whom left ventricular 
hypertrophy developed or persisted (28%)). Antihypertensive 
agents that are roughly equipotent in decreasing bload 
pressure may differ in ability to reverse I& ventricular 
hypenrophy. For exnmple, atier normalization of arterial 
pressure with vasodilators uch as hydraltine or minoxidil, 
muscle mass may remain unchanged despite adequate blood 
pressure control (64). In contrast, alpha-methyldopa pm- 
moted a reversal of left ventricular hypertmphy, whereas 
diuretic drugs had less consistent cticcts on hypcrtrophy 
although they reduced blood pressure to tbe same degree 
(65,66). This heterogeneity in the regression of leti ventri~ 
alar hypenrophy may be due to activation of the renin- 
;mgiotensin-aldorterone system. Current knowledge regard- 
ing drug specificity and efficacy m mediating a regression in 
left ventricular hypetlrophy is limited and based on a com- 
parison of sequential studies of which few were designed in 
a controllect. randomized manner. 
To examine this issne. (I mera-analysis of I@? sradtes MS 
p4mned despirr inherent weokmsses of such on ap- 
preach. Of the I04 studies identified on commercially avail- 
able data bases. only 8 were randomized placebo-controlled 
Overww analyses such as this roost he interpreted wnh 
all due c~uL~oo. ad quantitative comparisons cannot be 
drawn However. II is probable tha: mherear biases would be 
equal for ail trearmenr~. This meta-analysir sopQorts the 
finding ihar angiotenrin-converting enryma inhibitors. cal- 
cwn channel blocker5 and heia-blockers are effective in 
reducing venhicolar mass. Nondihydropyridines appeared 
to be wper~or to dihydropyridine calcium channel blockers. 
Prwpeclive randomized and controlled Studies are needed !o 
addrev coronary Row reserve. the reparation of the hypr- 
rrophied hean and remodeled cardiovascular synem, ~1 well 
as rc$rc,sion in left ventricular hypertrophy. Such audies 
should dam-mine whether cardiovascular morbidity and 
mortality will he reduced with a reduction in myocardial 
mar. It cdn be suggested from present limited informaion 
that !eft rentricular function is not imoaired when lef! 
venl?:ulzr hypenmphy is reversed in humans (67) and may 
even ix Improved (68). Preliminary mformation now sag- 
gem., that reversing left venirieolar hypertroQby (as assessed 
hy echocardiography) or preventing its occurrence in hu- 
mans results in Fewer cardiovascular events (631. 
Heart treatmen! trials: reparation. Collagen deposition is 
Figure 3. Effecl of antihypertenswc therapy on left ventncular 
hypenrophy. ACE = angiutmsin-eonvenmp. enzyme: LVM = left 
a major component of the remodeling process seen in left 
ventricular mass (index): PW = golleriar wall thickness. Re- 
ventrular hypenrophy. The noninvasive clinical assess- 
printed with permisnon. from Crwckshank IM (5% menl of collageo deposittan remains rechnicatty limited, 
neceersirating its investigation in animal models 
comparisons, 22 were randomized acwe comparisons and cling of the nonmy&te eot&rIment of the myocardnon 
74 were uncontrolled. Within the 104 rludies. 147 treatments occurs. This remodelina. which includes the acctatnlation of 
were analyzed involving >Z.wO hypertensive subjects. The 
greatly among studies. Percent ehonges in left vemricular 
roass (index). posterior wall thickness and interventricular 
number of patiena and the duration of treatment varted 
septal thickness were extracted and related to the decrease 
in mesn arterial pressure and the duration of treatment. Each 
data point was wrighted by the number of patients on which 
it was based. Drug classes were compared by weighted 
analysis of variance. Overall F teblz were used to assess the 
presence of any class differewes and were followed by 
individual I tats of specific pairs of classes. 
Reversibility of /eft ventricrdnr hypmrophy was sign$i- 
confly related 10 duration OJ rnamcnr and the exwnt oJ 
reduction in blood presswe. Figure 3 shows the percent 
change in left ventricular mass (index) and posterior wall 
thickness with the various treatmenrs. Drug differences in 
reversing left ventrieolar mass (index) were indepndent of 
treatment duration or decrease in blood Qressure: 1) an- 
ing of bese vessels 69): represents a determinant C. parho- 
fibriilar collagen withd the ittterstitium and adventitia of 
logic hypertrophy tha1 leads to ventricular diastolic. and 
ol&nately sys&lic, dysfunction that Qrovldes the basis for 
intramvocardial coronaw arteries I301 and a medial thickeo- 
the occorrertce of heart failure (70). It has been demon- 
strated that various pharmacologic agents that interfere with 
the adrenergic nervous system when giver. done or in 
combination may induce a regression in myoeardial mars in 
12.week old spontaneourly hypertensive ratdfs with left vew 
trieular hyQenrophy. However. myocardird col!agen eon- 
centration was found to increase with regression in left 
ventricular hypenrophy and reduction in myocyte size (71). 
Hence. the regression in left ventricular hypertrophy medi- 
ated by these agents conceivably led to an even greater 
heremgeneity in mywardial stroctore than was evident 
before their administration. 
giotensin-converting enzyme inhibitors &e significantly inhibirion in reversing fhism&ririol and vasc& n-mod- 
(p < 0.05) more effective than vasodilatorr, dihydropyridine e/inx in the rat with genetic hypertension and established l ft
calcium channel antagonists and beta-adrenergic blocking ventricular hyprtropby. 14week old male spontaneously 
agents; 2) methyldopa was more effective (p < 0.05) than hypertensive txs were treated for 12 weeks with oral lisino- 
vawlilators and dihydropyridines; 3) beta-blockers, diuretic pril (average dose 15 mgikg body weight per day) (72). 
drags and nondihydropyridine calcium channel antagonists Myocardial &4oess and coronary vascular reserve to aden- 
were all more ctfcctive (p c 0.05) than vasodilators; and “sine were examined in the isolated heart; myocardial cd- 
4) combination therapy was more effective (p < 0.051 than lagen and intramaral coronary artery architecture were 
vawdilators and dihydropyridines. analyzed morphometrically by videodensitometry. In COB- 
parison wth basclinc values of I+weck old or 2bweck old 
untreated spontaneously hypcrtenstvc rals and age- and 
gender-matched Wia.r Kgoto control rat,. rats treated k’ith 
lisinoprii had II normalization of blood pressure and a 
regression in left w~tncoler hypertrophy; 2) a complete 
regression of interstitial fibrosis: 31 normalization of myocar- 
dial sliffness; 41 a reversal of intramural coronary artery 
remodeltng. mcluding a normahzation of perivascular libro- 
sis and medial thickening of theye myacardial resistance 
vessels; and 51 a restoration of coronary vasoddator reserve 
to values seen m genetic control rats (721. Thus. in sponta- 
neously hypertensive rats with left ventricular hypertrophy 
and adverse st~ucturai remodeling of the cardnc intersti- 
Gum, lismopril ‘was able to reverse fibrous tiwe accumula- 
tion and medial thickening of irdramyocardial coronary 
arteries and to restore mvocardial stilTncss and coronary 
vascular reserve IU normal. Other invcstigatorr (731 have 
shown that myocardial hydroxyproline conrent decreases in 
spontaneously hypertensive rats treated with oral caplopril. 
and this decrease is associated with a reduction in collagen 
synthesis. Similarly, calcium channel blockade with oral 
nifedipinc was able to reduce myocardial tibrobls (measured 
by lefl ventricular hydroxyprolinc conccntmlion) and 10 
normalize blood pressure and reduce left ventricular hypcr- 
trophy m genetic hypertension after 20 weeks of treatment 
(74. 
Lerslnvorublr rerrd/~ wcrc obaiwd wirh 6 we1(.~ of orrd 
capto,oril fremnen~ in IUS wirh runostnwlnr h?pwmsinn. 
which caused an increase m collagen concentralmn that 
aazompardx! the regression in lefl ventricular hypcnrophy 
(75). The cnplanatmn for these ditTerences in response 
between spontaneously hypenensivc rats wilh genetic hy- 
peltension and thaw with acquired hypertension is un- 
known. Pofeotial considerawns include d!tTerences in drue. 
dosage or the duration of therapy, because a regression in 
myocyte size occurs more ouicklv with normalization of 
blood prewne than does col&en.degradation, which i? a 
s,ower proce.s (76,. Therefore, the effects of I2 weeks of 
treatment with oral zofenopril. labetalol or nifedipine was 
compared in K-week old Sprague-Da&y rats with estab- 
lished left w?!ricular hypenrophy due to R-week renovas- 
cular (2.kidneys. I-clird hvoenension. Zofenowil resulted in 
signiBcant r&sion bf n$cardial fibrosis and left venrric- 
ular hypertrophy as well as normalization of blood pressure. 
In contrast, labetalol showed no effect on myocardial colla- 
gen accumulation although arterial pressure was controlled 
and the extent of reduction in myocardial mass was similar 
to that induced by zofenopril. Nifedipine produced signifi- 
cant regression of both interstitial and pericardial fibrosis 
and !eft ventricular hypertrophy. 
These provocative findings regarding myocardial repara- 
tion in rats with acquired or generic hypertension will require 
confimration in humans. Nevenheless, (hey suggest the 
possibility of restoring myocardial structure to normal m 
promoting a regression in left ventriculnr hypcrtrophy and 
not simpl;! P rcducten in ventricular mass 
Curonary circulation. In patients with arterial hypertcn- 
sion. the coronary varoddalor reserve ts frequently tmpaircd 
even when epicardial coronary arteries arc anatomically 
normal m appearance. Maximal coronwy blood Row after 
dipyridamole administration is reduced by 30% to 50% and 
minimal coronary resistance is accordingly increased. Cor- 
onary vasodilator reserve (i.e.. the ratio between coronary 
resistance at rest and that observed under maximal vasodl- 
lation) is likewise reduced relative to that seen in normoten~ 
we persons. Mcasurcment of coronary Row reserve allow5 
for the determination of the functional impairment of coro- 
nary regulatory capacity and. consequently. the evalwaion 
of microvascular angina (771. 
The in~poirnzmr ofcoronory vnsodilaror merve in WY- 
hl hyperrtmivn can be attributed primarily to structural 
alterations in coronary resistance vessels (vascular compo- 
nent). Myocardial hypertrophy (myocardial component). 
may also contribute through extravascular compressive 
forces that elevate co:onary resistance or by enhancing 
blood Row requirements under basal conditions. Interstitial 
and perivascular myocardial fibrosis may reduce cororary 
reserve by increasing the myocardisl component of caronar) 
resistance. In left ventriculx hypertrophy of moderate se- 
verity, the redurdon in coronary flow reserve is not propor- 
tional to the increase in left ventricular mu& mass (78). 
which indicates that the myocardial factor, expressed indi- 
rectly as echocardiographic left ventricular muscle mass. 
does not directly determine the reduction in vasodilator 
reserve. Moreover. Brush et al. (791 demonstrated impaired 
Row reserve in hypertensive patients without left vent&ular 
hypcrtrophy. Hypertensive remodeling of the coronary mi- 
crocirculation includes I) alterations in the composition of 
the vessel wall leading lo a decreased vandilator capacity, 
and 2) a reduction in the number of parallel vascular paths 
ways in the myocnrdium that can be provoked by a dirpro- 
portionale growth response of the myocyte col+&nent 
without B corresponding growth adaptation of the coronary 
resistance vessels or capillaries. 
Rwmrly. medial rhickming of inrmmurol coronrrry ar- 
r&es in viva nws demonsrrawd in hyprrrensive patients by 
morphometric evalualions of transvenous endomyocardiai 
biopsies. HypertcAe pitlirnls with severely impaired cur- 
onary rewve were found to have a si.enificantlv meater 
percent wall area in resistance ~cs~cl~ (70-t 9 versus 61.2 ? 
9.2%; p < 0.05) than that seen in patients with lesr impaired 
coronary reserve, and their minimal coronary resistance LO 
dipyridamolc was correlated with the wall area of these 
re&tance vessels fp < 0.05). However, limilatiow in sample 
size. tissue fixation procedures and regional variations may 
limit the interpretation of these data. 
In addition to structural factors that may contribute to the 
impairment in coronary vascular reserve in left ventricular 
hypenrophy, a~cenuations in rndotheliurr-mediated comrol 
of coronary resistance vessels may also exist. Impaired 
endathelium-dependent coronary vasodilation in response to 
acetykholine was obse:ved in preliminary studies in patients 
wth established essenlial hypertension. a findmg that wnuld 
be consistent with alteration of the endothelium-derived 
relaxing factor system in human hypenenwn (731. 
In recent years it has been shown that lett vemr~~utaf 
hypertraphy can he reversed by amlhypcrten,ive agents. 
More information regarding ability of these agents IO repax 
coronary microcirculation is needed. In ~pontx~eou~ly 
hypertensive rats. enhanced coronary rewrve without a 
concomitant regression of left ventncular hypenrophy oc- 
curred after hydralazine treatment 1801. whereas administra- 
tion of the calcium amitgonist fetodipine Icd !z 2 reversal of 
medial hypertrophy in coronary resistance vessels WL In 
these rats. iiinopril improved cownary reserw and re- 
versed both medial hypertmphy and myocardial fib&r 
(72~. whereas other angiotensin-converung enzyme inhibi- 
lors reduced arterial medial thickoeqs 182.83). Finally. Mall 
21 al. (84) found a reduction in the volume density of 
myocardial fibrosis, adecreare in arterial Pedlal volume and 
an increase in the length density of capdIaries with ather 
nifedipine or moxonidine. 
Resistance vessels. Although many fxtors may partsi- 
pate in the pathogenesis of hypertension, the physics1 cause 
of established essential hypertension is mcreased vascular 
resistance (22). which is largely due to structuml abnormal- 
ities in !be peripheral vasculatu~. Many of these vascular 
abnormalities appear 10 be adaptive changes that allow the 
vascular system to maintain the high blood preswre more 
effectively (85). The relation between hypertension and 
abnormalities of the proximal resistance vessels was studied 
with the use of an isometric myograph (86) and isolated 
segments of resistance vessels obtained from spontaneously 
hypertrnsive rats and patients with essential hypertension. It 
was found that the ratio of the thickness of tunica media to 
lumen diameter was increased under relaxed and pressurized 
conditiuns (87). This structural abnormality can account for 
the increased pressure response seen in hypettenston. His- 
tomorphametric investigations, however. have provided 
conflicting evidence as to whether the increased medial 
lumen ratio is also associated wifb growth (88). and it is 
possible that the altered structure is due to redistribution of 
existing cells (89). Rege.x!!~ss of the basis for the altered 
structure, it appears that in essential hypertension the al- 
tered vascular structure is in itself sufficient to explain the 
increased peripheral resistance (87). 
Antihypertensive treatment mitiated in young spontane- 
ously hypertensive rats was found (90) to be more eflective 
in preventing an increase in blood pressure than in control- 
ling vascular structure m proximal resistance arteries. Sim- 
ilar results were obtained with vessels taken from patients 
with essential hypertension after at least I year of’-atment 
(91). These resttlts are consistent with hemcdyoam.i studies 
in patients with essential hypertension, in whom treatment 
also fails to fully correct hemodynamic vanablcs (92) unless 
it is condnued for many years (93). HistomorphDmetric 
investigations of resistance vessels (94) have indicated min- 
imal effects on smooth muscle cell volume and cell number 
derpw known vanability m Ihew me~wrcments. Vore 
weci;lc wabi d correctinE vascular stiuctuie are therefr:re 
needed iX?l It has bein sudgeited that angiotenw- 
conrcr~m: enzyme IACE) inhibixrs ma: Se mox ci?eeeaive 
than other drugs m comc~ing oscular ~tmcturr CG.83.95, 
961. Chrwenrcn et al. PO). houever. failed fo demownte 
such speed% effects of ACE inhibmxs. A recent analy& by 
Chnstcnsen (97.98) su~ested that the blood treasure YXI- ._ 
able of imporunce to v.scuIar structure is pulse pressurr 
rather than mean pressure: the analysts suggested [ha< fuli 
cwrecwx of vascular ~truetme could be Qbrained il p&e 
pre~urc war normalized. 
Myoeardium. In response to increased load. the mtact 
hean undergoer several adaptations involving changes m 
cardnc seome~ry. shape and strwt~re. In some but not all 
CIS;E. Liisruption of the collagen infrastructure ic a key 
mechamsm of side to side mywyte slippage (99). 
Tiw implirorions of these cbnnges in cardine archirecwe 
on rhu perfoornroncr of lhe intact heart are many and raried. 
One early sign alsydalic ventricular disease is alteration m 
the normal sequence of early systolic events wtth premawe 
minor ans sbonening and delay of longitudinal shortening 
(1001. Changes in cardiac geometry wab .S shift from ibc 
conventional elliptic to a more globular or spheric shape 
accommodate a greater chamber volume ba result in a 
mechanical dnadvantage. Indeed, evidence now exists 
1101,102) to indicate that in comparison with heans of 
similar thickness and size, hearts that become more 
globular are asswziated with diminished exercise perfor- 
mance. a greater likeiihwd of development of heart failure 
and ultimately a worsened prognosis. Another important 
functional consequence of collagen accumulation and re- 
modeling may be its adverse influence on diastolic relaxation 
and stiffness (103). 
Remodeling: of rhe left ventricle is ofporricular rrkvonce 
ro patiems ~rrh @large. usually anterior. myocardial infarct 
1lW. The resultant infarct expansion and segmemal dilarion 
mediated by left ventricular wall thinning is associated with 
myocyte necrosis. cell rupture. stretching of existing myo- 
cytes. slippage of myocyte grouos and reduction in the 
intercellular space. Disruption of the myocardial collagen 
matrix has been observed in an experimental canine model 
of stunning (105). When tbe infarct is substantial and trans- 
mural, there IS a significant impact on the noninfarct 2one 
wth the development of regional hypertrophy to compen- 
sate for poor function in the infarct zone. There appears to 
be a finite bmit to the hypertrophy that may be imposed by 
the limitations of available energy substrate (106). The 
depletion of energy substrate at end-stage hean failure is 
associared wtb funher cbanher dilation and mywardml 
thinning. Remarkable recovery of left ventricular dysfmx- 
tion mediated by revascularization has now been dacu- 
mented (107) in patients with chronic coronary ariery dir- 
ease who have left ~enmcokw bihcmario,~ Rapid. efiective ore caused by chronic valvular disease. cyanotic congenital 
and sw?ined reperfo\ion of occluded coronary aflcric\ IS hean disease or hpperlcnsiun may include interstilial edema. 
the moot ~mponam repawe rtrawgg for acme myocardml vascolar hyperrrophy and fibrosis and vdriuo~ glomerular 
infarciron changes. These rathw wnspecific changes occur less fre- 
Ii ULNA wcm.~ c lrrw riarr u~cnr.\ ~willi rlie < opm I,? 10 imp:or quenlly in paliemr with myocardi-1 failure. 
iwolin~ 4orrld hc owidcd in r/w NV/~ posnnyoca~dird .Kclrru: ~mt.~clc. Perhaps because fadgue and exercise 
bfuwrion period LO as 10 minimize rhe wwptihility of the 
damaged left ventricle to the defoxoation \tresse~ that CXISI. 
Steroid\, ibuprofen and indomethacin hsve all been demon- 
strated Io be dcleleriour in this regard (100. 
onaior norm-ro,r l,rriing mzynw (AC&) bd~ihiror rhrrupy in 
attenuating or preveoting progressive ventricular cnlarge- 
ment after major myocardial infarction, both clinically and 
experimentally. Simdnr benefitc have been reported with 
wstained mlmte therapy (104L 
The mechanism of the striking survival benefit of ACE- 
inhibitor therapy in patient5 with advanced symptomafic 
heart failure remain unckar. Given [he interesting new data 
that highlight the capacity of ACE-inhibitor therapy to 
reverse cardiac fibrous tissue accumula!ion and medial 
thickening of mtromyocardial coronary xl&s in the span- 
taneously hyperlenive rat with left vcntriculnr hyperlrophy. 
il is temfxmg to speculate that lhe dir& t~ssoe effects of 
AC!+inhlbimr therapy may be clinically rclcvant 021. 
Rripbwal tisues. Many of the manifeblations of heart 
failure are mediscd thmugh ellermioos in the structure and 
fun&n oCnoncardmc !issucs Ihal perpetuate this condition 
and often evoke unique conip!icaling problems. With the 
excep~on of remotely performed ppihologic studiev (I I I). 
most of which were performed m patients wlh chronic 
severe nonsurgically treated valvolar heart disease (mitral 
stenosis. for example), remarkably little information is avail- 
able on the histology and ultrasfruciure of noncardiac organs 
in chronic heart failure. It is generally appreciated that 
chronic passive congestion of the liver leads to loss of 
intolerance are common fealurcs of hesrt failure. skeletal 
muscle is the most studied peripheral sm~ctore in this 
condition. Mancini et al. (112) and Sullwan et al. (I 13) noted 
a reduced perccm of slow twitch foxidauve) type I fibers, a 
resultam r&c in the relative percem of type 11 fast twitch 
(glycolytic) hbers and some atrophy of Ila 2nd Ilb fibers in 
patients wrh chronic congestive heart failure compared with 
normal subject,. Drexler et al. (I 14) found that the size and 
membrane area of thi mitochondria of skeletal myocytes 
are decreased in heart failure. On the basis of these dnd- 
iogs. it is somavha p&i: t a ble that the oxidative enzyme 
acdi.ily and iis products (high energy phosphas) should 
be depressed in chronic hesn failure. Indeed, it has been 
found that the activily of several oxidative enzymes of 
skelelal muscle are sigoificantly depressed in chmnic con- 
gestive heart failure II 13.1151. In addition. the concentra- 
tion of lipolytic enzymes appears to be reduced (I 12.11~). 
These dltemlions in stroclure and function are likely to 
conrributi io the development of ibe lnetaholic d.-nope- 
menls of skeletal muscle in heart failure during exercise, 
namely higher inorganic phosphate cancenlralions. lower 
high energy phosphate levels. lower energy stores and 
generation. increased lactate production and concentrationn, 
lower pH and greater fat&e for any amount of exercise 
(I IZ.Il6). Although considerable a!len:ion has beendirected 
toward impaired &ygen delivery and limb blood flow during 
exercise. much of the exercise intolerance in chronic heart 
failure i, probably due to these anatomic and physiologic 
derangements. Many of these alterations and their metabolic 
and functional consequences appear to be reversible 
(117,118!. 
Ne~uolrwwrtr/ snd hormml fimrr. In moderate to 
severe chronic congeslive heart failure. anatomic and impor- 
tant fimcl~onal alterations occur in systemic vasculatore that 
accentuate the already heightened aortic oulflow impedance 
and ventricular afterload. Various neurohumoral and hor- 
monal faclors in hear! failure favor vasoconstric~ion. In- 
hepatocytes. fibrous replacemeot and cirrhosis; sigmficant creased vascubx @oess. in part secondary LO increased 
hcpatic dysfunction may then complicate the heart failure sodium content of the vessel wdl, con;ributes to the high 
syndrome with hypoalbuminenao. accentualion of the renin- vascular impedance and impaired varodilator re~ponsivc- 
angiotensin-aldosterone system, worsen;lg edema and ae- ness in heart failure and is largely reversed with diuretic 
cites, inadequate drug metabolism and of,xr abnormalities. therapy (119). 
In chronic mitral stenosis. there is B thickenine and fibrosis 
of alveolar septae, thickening of basement membranes. 
fibrous rrnlacement of alveolar omts. eeneralized inlerslilial Diaberrs 
fibrosis, &led lymphatics and hypenrophy and fibrosis of Diabetic rardiomyopnthy. Diabetic cardiomyopathy is a 
pulmonary veins and aTIer&, all contributing IC ao cxocer- hear1 muscle diseax associated with diabetes mellitus (types 
bation ofabnormalibes in gas exchange and oxygen delivery. I and II) that is independem of coronary atherosclerosis 
This nsmod&g is porn& b&c& LU be irss promiocot in (120,121L The heart in patients with diabetes has increased 
myocardial failure. Renal structure alterations in heart fail- weight (1?0.121). Hislopathologic studies (122.123) in exper- 
imental animals and humans reveal changes that span the 
spectrum from minimal change to advanced myocyre hyper- 
trophy and fibrosis. The severity of diabetes is a major 
dcterminrnt of myocardial patbologj m rati w;h alloxan- 
induced diabetes (123). Focal perivasculer damage wth lox 
Of contractile elements and deposttmn of penodic acid- 
Schiff-positive material or 9lycopmtein iq seen (121). Ven- 
tricolor expression of a fetal genetic pattern follows induc- 
tion ofdiabetes in experimental animals, for example, a shift 
in myocardial myosin isozyme from leads V, to V, and 
expression of messenger RNA for atrial natriuretic fdctor 
(1’24-126). Abnormal left ventricular diastolic furawn has 
been dctxanstrated in isola!ed haxt preparations frua rats 
with early diabetes (124). bv cardiac catheterization fi dines 
in diabetic dogs (127) and humans (128) and by echocardio- 
graphic findings in humans (129). Left ventricular systohc 
dysiunction may be brought about by imposition of circula- 
tory stress 1130) and may become manifest at rest as heart 
failure develops (IZO). 
The pothaphysiology of diaberic cardiomyopsrhg may in- 
VOlve nanenzymatic &cosylation of pmteins, cardioneuropa- 
thy and disturbances in lipid and calcium metsbolism t 120. 
124). A decrease in cardiac cell surface beta.adreweptors 
impairs inotmpic responses to br!a-adrenergic stimulation 
(131). In addition, abnormalities in sarcolemmal sadium- 
potassium edentine triphosphata! and calcium metabolic 
activity have been observed in diabetic admals (124). Lesions 
of the small emwary vessels may also play a role in more 
advanced siages of the disease (:5li. Atrhough many of the 
mycardial abnormalities in diabetes may be corrected with 
insulin, hypen’nsdiwmia may also contnbute m the pathogen- 
esis of the cardiovascular hypertmphy owing co insulin’s 
growth-pmmoting propertier. 
Diabetic cardiomyopathy alone is ssldom sewx eiths, isI 
experimental animals or in diabetic humans (120,121). How- 
ever, when diabetes is associated with systemic arterial 
hypertension. cardiomyopathy may become severe. Hean 
weight and myocerdial fibrosis were greeter for hypertensive 
diahedc patients than for those with diabetes or hyperten- 
sion alone (122). 
Diabelk ocular lesions. Diabetes mellitus is considered 
a risk factor for atherosclerosis. However, the fundamental 
structural vascular lesion in diabetes consists of increased 
thickness of the basement membrane in small blood vessels. 
The pathogenesis of Ihe lesion is not known but high glucose 
concentrations induce expreraion of messenger RNA for 
type iii collagen end fibronectin (132). Because the die&c 
animal is genetally hyporenittemic one might infer that the 
activity of the entiir renin-angiotensin-aldasterone system IS 
low. However, experimental diabetes p:oduces an increase 
in circulating angiotensin-converting enzyme (ACE) activity 
(133). end pabx~sary .ACE levels !cnded to increase as well. 
In the chmnicel!y di5zic at. an increase in aorti; reninlike 
activity WLF found (134). Thus, the tissue renin-angiotensin- 
aldosterane sys!em may be important in the vascutar corn- 
phca:~ons of &abetes. perhaps by awing vascular perme- 
abihtv ? :;milar condition rmght he present in the heart (30). 
Treatinent. In experimental animals withom advanced 
dwace. msutiil treatment rcs1?11s in resmraiion of fun&n 
It241 and in reduction of circulating ACE levels 1133). 
Trearment of experimental diabetes in rats with L-camitine 
and coenzyme @IO have resulted in improved cardiac func. 
ho” (124). Prevention of changes in vawlar basement 
membranes and cardioneuropathy due to abnormalities in 
the rorbllol pathway might be correcud by using aidore- 
reductase Inhibitors (135). Because of the possible roles of 
the renin-angiotensm system and abnormal calcium metab- 
olixn in the pathophydology ol the diabetic hean. ACE 
mhibitors and calcium antagonists might be of therqatic 
btnefit. 
Conclusiorps 
Cardiac myocytes. endothelial cells, vascular smooth 
muscle and iibroblasrs form the cell population of the car- 
diovascular zzstem. Alone or in combination, hypertrophy, 
hypaplzwa and altered metabolic function of these cells 
produce structr~ral remodeling of rhe myocxdium end we- 
rial vacculature that may be expressed functionally as arte- 
rial hypenension, myocardird dysfuwion or renai Failure. In 
Ihe hypertensive patient, left ventricular hvoertrophy is a 
gacd exam?!e of abnormal stmrtwe and f&ion’th& are 
associated with increased cardiovascular risk zud :educed 
life expectancy. 
The prevention of structural remodeling aed the repam 
t;on of altered structure to or toward normel are therapeutic 
g&s !ha! rzy redoce cerdiovacsulnr morhidi~y md monnt- 
ity. Although this hypothesis has been proved. it is clear that 
the primary goal of therapy should ix to preserve or to 
restore h~sue strecture and function. 
We have reviewed the cellular and stmctuml basis of 
fissur remodeling and its expression as hypertension and 
heart failure in experimental nmdels end in humans. We 
have funher considered the pm&es of circulating, locally 
genemted substances that can influence the growth polential 
and metabolic behavior of myocyte and nomnyoeyte cells 
and phamucologic agents that may induce reparetian of 
the stmcturally remodeled myacardhtm ard vasculature. 
We have especially focused on the renin-angiotensin- 
aidosterone system thaf appears M bo an additioal predictor 
of morbid events, independent of Isft ventricuw hywtm- 
phy. Vc IN@ that the illt2,sdtediSLderWiUfind this auMtd 
discussiw that wil: set the stage for hturr rsientific inquiry. 
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